ASAP TOO trial to evaluate the use of the WATCHMAN Device in patients unsuitable for oral anticoagulation, which could lead to expanded labeling in the U.S. Strategic Acquisitions In than a dozen strategic investments in support of our category leadership strategy and to enhance our presence in faster growing markets.